AH-7921
AH-7921 is a synthetic opioid analgesic that was first synthesized in the 1970s by a team of scientists at Allen and Hanburys, a pharmaceutical company. It is known for its potent analgesic effects and has been compared to morphine in terms of its efficacy.
Chemical Structure and Properties[edit]
AH-7921 is chemically classified as a benzamide. Its IUPAC name is 3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide. The compound has a molecular formula of C16H22Cl2N2O and a molecular weight of 329.26 g/mol.
Pharmacology[edit]
AH-7921 acts as a potent mu-opioid receptor agonist. It binds to the mu-opioid receptors in the brain and spinal cord, which are responsible for the analgesic and euphoric effects of opioids. The drug has been shown to produce effects similar to those of other opioids, such as morphine and heroin, including pain relief, euphoria, and sedation.
Medical Use[edit]
Despite its potent analgesic properties, AH-7921 has never been approved for medical use. Its potential for abuse and addiction, along with its adverse effects, has limited its development as a therapeutic agent.
Adverse Effects[edit]
The adverse effects of AH-7921 are similar to those of other opioids and can include:
- Respiratory depression
- Nausea and vomiting
- Constipation
- Drowsiness
- Dependence and addiction
Legal Status[edit]
AH-7921 has been classified as a controlled substance in many countries due to its potential for abuse and lack of medical use. In the United Kingdom, it was classified as a Class A drug under the Misuse of Drugs Act in 2015. In the United States, it is listed as a Schedule I controlled substance under the Controlled Substances Act.
Synthesis[edit]
The synthesis of AH-7921 involves the reaction of 3,4-dichlorobenzoyl chloride with 1-dimethylamino-2-cyclohexylmethylamine. The process requires careful control of reaction conditions to ensure the purity and yield of the final product.
See Also[edit]
References[edit]
External Links[edit]
 | This medical article is a stub. You can help Wikipedia by adding missing information. |
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends ✔ Tele visits available with certain limitations Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
- Budget GLP-1 shots
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
